Merck Is Printing Money and Losing Money at the Same Time. Both Are True.
A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point...
A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say
The gist of it Sarepta's filed numbers tell a story of a company that briefly turned...
The Quiet Compounder at a Loud Price: What Royalty Pharma’s Filings Actually Say
Royalty Pharma's stock sat at an all-time low in December 2024. By late August 2026, it...
Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say
Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at...
ExxonMobil: A Machine That Prints Cash While the Market Argues About the Price Tag
The heart of it ExxonMobil's filed numbers show a company generating more free cash in a...
Home Depot: The Stock Is Down a Fifth, the Business Just Beat Estimates. Something Has to Give.
Here is the tension in one breath: Home Depot's stock has fallen roughly a fifth over...
One Drug Carries the Weight: What Regeneron’s Filed Numbers Say About the Price
Dupixent's global net sales grew 38% in a single quarter. The stock is priced at a...
Netflix Is Earning More Than Ever. The Stock Is Down 37%. Both Things Are True.
The gist of it The filed numbers show a business that has nearly doubled its profit...
Goldman Sachs Is Earning Like It’s 2021. The Market Is Pricing It Like Something Better.
Goldman Sachs spent most of the last decade trading below the value of its own assets....
Lowe’s: The Stock Is Down a Quarter, the Business Just Grew 10%. The Gap Is the Story.
Six years ago, Lowe's was the perpetual runner-up, a perfectly decent hardware chain that always seemed...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.